Candidate: EXG-5003

Category: RNAVAX

Type: Temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein.

Status: Elixirgen said September 1 that EXG-5003 will be assessed in Phase I/II trials to be conducted by Fujita Health University through a contract from the Japan Agency for Medical Research and Development (AMED) whose value was not disclosed. Clinical trials are expected to begin at Fujita Health University Hospital in Aichi, Japan in Q1 2021, Elixirgen said.


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA

This site uses Akismet to reduce spam. Learn how your comment data is processed.